Real-World Data Show AUSTEDO XR Delivers High Patient Satisfaction and Movement Improvement in Tardive Dyskinesia
Key Insights
Over 94% of 209 tardive dyskinesia (search) patients surveyed reported movement improvement when treated with AUSTEDO XR (deutetrabenazine) extended-release tablets.
Patients demonstrated high satisfaction rates (>89%) with AUSTEDO XR treatment, with 96% expressing interest in continuing therapy.
Real-world phase 4 IMPACT-TD Registry data showed meaningful improvements across multiple quality of life domains after 3 months of treatment.
Teva Pharmaceuticals has announced compelling real-world evidence demonstrating the effectiveness of AUSTEDO XR (deutetrabenazine) extended-release tablets in treating tardive dyskinesia (search) (TD), with over 94% of patients reporting movement improvement and high satisfaction rates exceeding 89%. The data, presented at the 2025 Psych Congress Annual Meeting in San Diego, California, provides valuable insights into patient experiences with this once-daily VMAT2 (search) inhibitor treatment.
Patient Survey Results Demonstrate Strong Treatment Response
The noninterventional, prospective, cross-sectional survey included 209 participants with tardive dyskinesia (search), comprising 54 patients with prior valbenazine use and 100 treatment-naïve patients. Key findings revealed that both groups reported their uncontrollable movements were very much, much, or minimally improved once treated with AUSTEDO XR, with improvement rates exceeding 94%.
Beyond symptom control, patients experienced significant quality of life improvements. More than 77% of participants strongly agreed or agreed that their reduction in movements led to increased comfort in social settings and improved emotional well-being. The treatment's ease of administration was particularly notable, with 96% of patients with prior valbenazine use and 99% of treatment-naïve patients reporting that AUSTEDO XR was easy to take.
Patient satisfaction remained consistently high across both groups, with 91% of patients with prior valbenazine use and 89% of treatment-naïve patients reporting overall satisfaction with AUSTEDO XR. Demonstrating confidence in the treatment, over 96% of patients expressed interest in continuing therapy.
IMPACT-TD Registry Provides Additional Real-World Evidence
Complementing the patient satisfaction survey, data from the ongoing phase 4 IMPACT-TD Registry study further validated the clinical effectiveness of deutetrabenazine formulations. The analysis evaluated 27 adults with tardive dyskinesia (search) treated with deutetrabenazine or deutetrabenazine extended release, representing a real-world patient population with common psychiatric comorbidities including bipolar disorder (search) (41%), anxiety disorder (search) (37%), depression (search) (26%), and schizophrenia (search) (19%).
After three months of treatment, patients showed meaningful improvements across multiple domains: speech/communication (77%), eating (75%), psychosocial impact (65%), activities of daily living (59%), and sleep/pain (50%). Importantly, 85% of participants reported that their underlying mental health condition remained stable or improved based on the Patient Global Impression of Severity scale when deutetrabenazine treatment was used alongside their mental health medications.
The clinical efficacy was further supported by objective measurements, with the total motor score on the Abnormal Involuntary Movement Scale showing a mean decrease of -2.9 at three months, indicating notable reduction in the severity of uncontrolled movements consistent with previous clinical trials.
Clinical Significance and Treatment Impact
"When we look at tardive dyskinesia (search), it's not just the science or the data, but the real people who are facing the daily physical and emotional challenges of this disease," said Eric Hughes, MD, PhD, Executive Vice President, Global R&D and Chief Medical Officer at Teva. "At Teva, we feel a profound responsibility to ensure we're not just treating TD with the benefits that AUSTEDO XR can bring, but truly understanding the lived experiences of this community."
Stacy Finkbeiner, Senior Medical Director, Movement Disorders and Psychiatry at Teva Pharmaceuticals, emphasized the importance of real-world evidence: "The silent struggle of tardive dyskinesia (search), with its relentless, involuntary movements, can deprive patients of their quality of life and independence—real-world findings are so critical to inform how we innovate and improve the everyday lives of individuals living with this disease."
About Tardive Dyskinesia and Treatment Options
Tardive dyskinesia (search) is a highly debilitating, chronic movement disorder that affects one in four people who take certain mental health treatments. The condition is characterized by uncontrollable, abnormal, and repetitive movements of the face, torso, and other body parts, which can be disruptive and negatively impact individuals' daily lives.
AUSTEDO XR and AUSTEDO are the first vesicular monoamine transporter 2 (search) (VMAT2 (search)) inhibitors approved by the U.S. Food and Drug Administration for treating tardive dyskinesia (search) and chorea associated with Huntington's disease (search) in adults. AUSTEDO XR represents the once-daily formulation of AUSTEDO, offering improved convenience and potentially enhanced adherence for patients managing this chronic condition.